U.S. Clinical Trials Supply And Logistics Market Size, Share & Trends Analysis Report By Service, By Phase (Phase I, Phase II), By Therapeutic Area (Oncology, Cardiovascular), By End-user, And Segment) - Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2024-2033

The U.S. clinical trials Supply and logistics market size was estimated at USD 1.90 billion in 2023 and is projected to hit around USD 3.95 billion by 2033, growing at a CAGR of 7.6% during the forecast period from 2024 to 2033.

Key Takeaways:

• Based on the end-user, pharmaceuticals dominated the market with a share of about 45.19% in 2023.
• The biological segment is expected to expand at the fastest CAGR of 7.7% from 2024 to 2033.
• Based on the services, logistics, and distribution held the largest market share of 25.13% in 2023 and is expected to grow at the fastest CAGR over the forecast period.
• The manufacturing segment is projected to grow at a significant CAGR of 7.7% from 2024 to 2033
• Based on the phase type, phase III dominated the market with a revenue share of 43.15% in 2023.
• The phase I segment is expected to grow at the fastest CAGR of 7.9% from 2024 to 2033.
• Based on the therapeutic area, cardiovascular disease held the largest market share of about 30.9% in 2023 and is projected to grow at the fastest CAGR over the forecast period.
• The oncology segment is expected to grow at a CAGR of 7.6% from 2024 to 2033.

U.S. Clinical Trials Supply And Logistics Market Overview

The landscape of clinical trials in the United States is constantly evolving, driven by advancements in medical research, technological innovation, and regulatory requirements. Within this dynamic environment, the supply and logistics aspect plays a critical role in ensuring the success and efficiency of clinical trials.

The U.S. clinical trials supply and logistics market encompasses a wide range of activities and services aimed at supporting the conduct of clinical trials, from the initial stages of planning and design to the final stages of data analysis and regulatory submission. This market includes various stakeholders such as pharmaceutical companies, contract research organizations (CROs), logistics providers, and regulatory agencies, all working together to facilitate the timely and accurate delivery of investigational products and materials to clinical trial sites across the country.

U.S. Clinical Trials Supply And Logistics Market Report Scope

U.S. Clinical Trials Supply And Logistics Market Growth

The growth of the U.S. clinical trials supply and logistics market is propelled by several key factors. Firstly, robust investments in research and development by pharmaceutical companies and biotech firms drive an expansion in clinical trials, stimulating demand for supply and logistics services. Secondly, the escalating complexity of clinical trials, characterized by precision medicine and targeted patient groups, necessitates agile and scalable supply chains tailored to each study's unique needs. Thirdly, stringent regulatory compliance requirements mandate adherence to rigorous quality standards throughout the supply chain, ensuring the safety and integrity of investigational products. Additionally, technological advancements such as blockchain, IoT, and AI enhance supply chain management by enabling real-time tracking, inventory optimization, and enhanced transparency. Lastly, the globalization of clinical trials necessitates efficient supply chain solutions to manage product distribution across multiple regions, positioning the U.S. market as a pivotal hub for global trial initiatives.

U.S. Clinical Trials Supply And Logistics Market By End-user Insights

Based on the end-user, pharmaceuticals dominated the market with a share of about 45.19% in 2023, owing to many contract research organizations. The U.S. is the center for the operation of major players in the supply and logistics market, such as PAREXEL International Cooperation, Thermo Fisher Scientific, Inc., and Marken. Moreover, the availability of strong infrastructure, the necessary funds, and the ability to adapt to advanced technology fuel market growth.

The biological segment is expected to expand at the fastest CAGR of 7.7% from 2024 to 2033. This can be attributed to increasing demand for biological products, such as cell & gene therapies and vaccines, and increased product development investments. Biological companies are undertaking strategic agreements to improve distribution channels and customer reach, as well as to outsource clinical trial supplies and logistics to CROs to increase profit margins & expand their product portfolio in new markets.

U.S. Clinical Trials Supply And Logistics Market By Service Insights

Based on the services, logistics, and distribution held the largest market share of 25.13% in 2023 and is expected to grow at the fastest CAGR over the forecast period. This growth is driven by increasing biologics pipeline and growing usage of temperature-sensitive drugs. Logistics experts of various market companies handle the logistics and distribution of labeled or packaged clinical trial materials, comparator medicinal products, investigational medicinal products, etc. They are involved in geographical expansion to boost the growth of the market. For instance, in February 2024, FedEx, an International Shipping Company Headquarters in the U.S., launched the “FedEx Life Science Center” in India to build a strong clinical trial supply chain. This move would support the clinical trial storage and logistics requirements of healthcare customers within the Indian market and those shipping to India worldwide.  

The manufacturing segment is projected to grow at a significant CAGR of 7.7% from 2024 to 2033, owing to the high demand for material supplies, further increasing the demand for quality drugs. Complex molecules and high demand for biologics are expected to boost the manufacturing segment of the global clinical trial supplies market. Manufacturers of clinical trial materials and supplies are required to meet the supply needs of different phases of pharmaceutical clinical trials. They are also required to be fully GMP compliant. Many material supplies are outsourced, which drives the demand for efficient clinical trial supplies. Outsourcing in manufacturing can be attributed to introducing new technologies to manufacture complex molecules and increasing the demand for developing cost-efficient products.

U.S. Clinical Trials Supply And Logistics Market By Phase Insights

Based on the phase type, phase III dominated the market with a revenue share of 43.15% in 2023. Phase III trial is an essential stage for vaccine approval. Despite no or lesser incidences of COVID-19, manufacturers are still focusing on the new generation vaccine-manufacturing practices to prevent serious consequences of the disease shortly. As per clinicaltrial.gov, around 550 novel vaccines were in the development stage in 2022, which increased the number of trials that further contributed to the market's substantial market growth. Based on the phase type, phase III dominated the market with a revenue share of 43.5 % in 2023. Phase III trial is an essential stage for vaccine approval. Despite no or lesser incidences of COVID-19, manufacturers are still focusing on the new generation vaccine-manufacturing practices to prevent serious consequences of the disease shortly. As per clinicaltrial.gov, around 550 novel vaccines were in the development stage in 2022, which increased the number of trials that further contributed to the market's substantial market growth. According to a clinical trial logistics survey by Nice Insights, 35.0% of phase III clinical trials are outsourced, and the number is likely to increase owing to the growing number of investigational drugs advancing to the next phase.

The phase I segment is expected to grow at the fastest CAGR of 7.9% from 2024 to 2033. Phase I of clinical trials usually involves assessing a device's or drug's safety and evaluating the molecules' tolerability and pharmacokinetics. The increasing demand for drugs and clinical trials for assessing drugs are fueling the market growth over the forecast years.

U.S. Clinical Trials Supply And Logistics Market By Therapeutic Area Insights

Based on the therapeutic area, cardiovascular disease held the largest market share of about 30.9% in 2023 and is projected to grow at the fastest CAGR over the forecast period. This growth can be attributed to increased cardiovascular research projects and companies dedicated to bringing new medications to the market. As per CDC data, heart disease is a predominant cause of death in the U.S., and about 805,000 people in the United States have a heart attack per year. Considering this higher prevalence of cardiovascular disease, the demand for drugs is also increasing. An increase in demand for drugs further boosts the growth of the market.

The oncology segment is expected to grow at a CAGR of 7.6% from 2024 to 2033. This growth is driven by the increasing cancer incidences and the higher need for clinical trials conducted for cancer therapeutics. Clinical trial supplies in oncology include primary and secondary packaging. The primary objective of packaging is to improve patient compliance. Packaging must protect vials from leakage and gases from aerosolizing. Packaging should be done following the dosage requirement. According to the United Press International, hospitals in the U.S. are disposing of millions of cancer drug vials due to improper dosage.

U.S. Clinical Trials Supply And Logistics Market By Recent Developments

• In August 2023, Worldwide Clinical Trials announced the agreement of acquisition with Kohlberg & Company, LLC. This acquisition would lead to increased sales of Kohlberg& Company, LLC, and give a minority stake in the company.
• In June 2023, SkyCell announced a partnership with Marken to enhance pharmaceutical transport for clinical trials. This collaboration will provide Marken, the clinical trials logistics subsidiary of UPS Healthcare, with SkyCell containers designed for shipping critical and temperature-sensitive drugs. The partnership aimed at transporting and safeguarding temperature-sensitive clinical pharmaceutical supplies.
• In September 2022, Paraxel announced opening a new clinical trial supplies depot in China to help clinical sites and patients get supplies and drugs faster, as China remains a significant avenue for the growth of clinical trials.
• In March 2021, PCI Pharma Services announced the expansion of its Berlin facility's cold chain clinical supply storage and distribution capabilities through a significant investment that would give local clients access to the global market. Recent regulatory inspections that were necessary for these expansions at the Berlin facility were completed, and it is now fully functional.
• In January 2021, PAREXEL International announced the completion of the separation of its Informatics and Medical Imaging business. As part of this separation, Parexel Informatics was anticipated to become Calyx.

U.S. Clinical Trials Supply And Logistics Market Top Key Companies:

• Catalent, Inc.
• PCI Pharma Service
• Thermo Fisher Scientific, Inc.
• Marken
• Parexel International Corporation
• Piramal Pharma Solutions
• UDG Healthcare
• DHL
• FedEx
• Packaging Coordinators, Inc.
• PRA Heathsciences
• Myonex, Inc.

U.S. Clinical Trials Supply And Logistics Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Clinical Trials Supply And Logistics market.

By Service 

• Logistics & Distribution
• Storage & retention
• Packaging, labeling, and blinding
• Manufacturing
• Comparator sourcing
• Other services (solutions, ancillary supply)

By Phase 

• Phase I
• Phase II
• Phase III
• Phase IV

By End-user 

• Pharmaceutical
• Biologics
• Medical device

By Therapeutic Area 

• Oncology
• CNS & Mental disorders
• Cardiovascular
• Respiratory disease
• Others